ARTICLE | Company News
IRCM, Liphorus Pharmaceuticals deal
November 10, 2014 8:00 AM UTC
IRCM spun out Liphorus and granted the newco exclusive, worldwide rights to develop and commercialize technology targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). The newco plans to de...